Vapotherm, Inc. (VAPO)
| Market Cap | 560.49M |
| Revenue (ttm) | 125.73M |
| Net Income (ttm) | -51.50M |
| Shares Out | 23.82M |
| EPS (ttm) | -2.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $18.72 |
| Previous Close | $21.63 |
| Change ($) | -2.91 |
| Change (%) | -13.45% |
| Day's Open | 20.58 |
| Day's Range | 18.65 - 21.12 |
| Day's Volume | 577,996 |
| 52-Week Range | 18.65 - 54.42 |
Vapotherm (VAPO) delivered earnings and revenue surprises of 2.44% and 2.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...
Vapotherm (VAPO) delivered earnings and revenue surprises of 10.53% and 0.82%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
EXETER, N.H.--(BUSINESS WIRE)---- $VAPO--Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its propriet...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm's Hi-VNI technology is more comfortable and safer than current technologies used to treat patients with respiratory distress. The company has seen meaningful sales increases over the past two ...
Vapotherm, Inc. (VAPO) CEO Joe Army on Q3 2020 Results - Earnings Call Transcript
Vapotherm (VAPO) delivered earnings and revenue surprises of 19.67% and 26.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high ...
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif.--(BUSINESS WIRE)--CIBC Innovation Banking is pleased to announce a US$52 million growth capital financing with Exeter-based Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm”), a global medic...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high ...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high ...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of Vapotherm's proprietar...
Vapotherm (VAPO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Vapotherm - COVID-19 Comes To The Rescue
Vapotherm, Inc. (VAPO) CEO Joe Army on Q2 2020 Results - Earnings Call Transcript
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.
Vapotherm (VAPO) delivered earnings and revenue surprises of 10.26% and 20.80%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.
The company's products are getting exposure, thanks in part to the coronavirus pandemic.
The company released its fiscal first-quarter results.
Vapotherm (VAPO) delivered earnings and revenue surprises of -17.86% and 1.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Does Vapotherm (VAPO) have what it takes to be a top stock pick for momentum investors? Let's find out.
As of late, it has definitely been a great time to be an investor Vapotherm
Oxygen therapy has emerged as a necessity for COVID-19 patients.
Vapotherm (VAPO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Vapotherm, Inc. (VAPO) CEO Joe Army on Q4 2019 Results - Earnings Call Transcript
Vapotherm (VAPO) delivered earnings and revenue surprises of 16.67% and 6.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm, Inc. (VAPO) CEO Joe Army on Q3 2019 Results - Earnings Call Transcript
President & CEO of Vapotherm Inc (30-Year Financial, Insider Trades) Joseph Army (insider trades) bought 10,000 shares of VAPO on 09/04/2019 at an average price of $10 a share.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Vapotherm, Inc. (VAPO) CEO Joseph Army on Q2 2019 Results - Earnings Call Transcript
Vapotherm, Inc. (VAPO) CEO Joe Army on Q1 2019 Results - Earnings Call Transcript
About VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companio... [Read more...]
| Industry Medical Devices | IPO Date Nov 14, 2018 |
| CEO Joseph Army | Employees 397 |
| Stock Exchange NYSE | Ticker Symbol VAPO |
Financial Performance
In 2020, Vapotherm's revenue was $125.73 million, an increase of 161.38% compared to the previous year's $48.10 million. Losses were -$51.50 million, 0.87% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Vapotherm stock is "Strong Buy." The 12-month stock price forecast is 41.00, which is an increase of 119.02% from the latest price.